Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283887 | 0.79 | SCN2A (0.56) | ALDH1A1POLBSCN2AHSD17B1HSD17B2 | |
| SCHEMBL18316998 | 0.72 | KMT2A (0.54) | MEN1KMT2AALDH1A1HPGDAOC3 | |
| SCHEMBL29565561 | 0.69 | AOC3 (0.49) | MEN1KMT2AAOC3NPC1RAB9A | |
| SCHEMBL4628691 | 0.68 | SCN2A (0.44) | MEN1KMT2AALDH1A1POLBSCN2A | |
| SCHEMBL4628493 | 0.65 | MAPT (0.42) | ALDH1A1SCN2AHSD17B1HSD17B2NPC1 | |
| SCHEMBL13641355 | 0.65 | NPC1 (0.58) | MEN1KMT2AALDH1A1HPGDAOC3 | |
| SCHEMBL3718853 | 0.64 | ALDH1A1 (0.54) | ALDH1A1HPGDPOLBRAB9A | |
| SCHEMBL25975226 | 0.64 | KMT2A (0.49) | MEN1KMT2AALDH1A1HPGDAOC3 | |
| SCHEMBL4629476 | 0.64 | SCN2A (0.42) | MEN1KMT2AALDH1A1HPGDPOLB | |
| SCHEMBL7776491 | 0.64 | CYP1A2 (0.46) | KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | MEN1 1819/4885KMT2A 3245/4885ALDH1A1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.